Biologic tissue effect of sipuleucel-T on metastatic castration-resistant prostate cancer May 5, 2022 By Jesse Bufkin
A phase 2, randomized, double blind, placebo-controlled study of AeroVanc for the treatment of persistent Methicillin-resistant Staphylococcus aureus lung infection in Cystic Fibrosis patients May 5, 2022 By Jesse Bufkin
Intraoperative injection of bone marrow-derived stem cells into hearts of patients with end-stage ischemic cardiomyopathy undergoing placement of left ventricular assist device May 5, 2022 By Jesse Bufkin
AN OPEN LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB MCC DM1 (T-DM1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY TREATED WITH THE EQUIVALENT T-DM1 REGIMEN IN A GENENTECH AND/OR F. HOFFMANN- May 5, 2022 By Jesse Bufkin
Patient Outcomes 6 and 12 Months After ALTA, OMEGA, and EDEN ARDS Network Trials May 5, 2022 By Jesse Bufkin
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer May 5, 2022 By Jesse Bufkin
A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection May 5, 2022 By Jesse Bufkin
The RESPECT Study: Randomized EsophyX vs. Sham / Placebo Controlled TIF Trial May 5, 2022 By Jesse Bufkin
